{"id":534150,"date":"2021-09-02T16:23:04","date_gmt":"2021-09-02T20:23:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/"},"modified":"2021-09-02T16:23:04","modified_gmt":"2021-09-02T20:23:04","slug":"cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/","title":{"rendered":"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S."},"content":{"rendered":"<h2>\nRecruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong><br \/>\n          <sup>\ufeff<\/sup>Tel Aviv, Sept.  02, 2021  (GLOBE NEWSWIRE) &#8212; <\/strong>Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: \u201cAPOP\u201d), announced the first ApoGraft<sup>TM<\/sup> transplantation in a Leukemia patient in the Company\u2019s clinical trial at Washington University in the U.S. ApoGraft<sup>TM <\/sup>is a product based on the Company\u2019s cell selection technology designed to optimize immune therapy, in this application &#8211; prevent graft-versus-host disease (GVHD) following bone marrow transplantation.<\/p>\n<p align=\"justify\">Following the closing of the previously announced strategic merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraft<sup>TM <\/sup>development will be pursued by EnCellX, the privately held U.S. based company that is acquiring Cellect\u2019s proprietary technology concurrently with such merger. The trial will enroll 18 patients with hematological malignancies who are undergoing a haploidentical Bone Marrow Transplantation (BMT). EnCellX, led by Founder and CEO Adi Mohanty, is raising funds from leading healthcare institutional investors to expedite and expand clinical development.<\/p>\n<p align=\"justify\">\u201cThis is an important milestone for Cellect and demonstrates the team\u2019s professionalism and dedication for getting us to this occasion,\u201d commented Dr. Shai Yarkoni, Chief Executive officer. \u201cWe look forward to working closely with EnCellX as its U.S. based team will work closely with Washington University to continue patient enrollment. This achievement, following the release of positive topline data from the Israeli ApoGraft<sup>TM<\/sup> trial, is timely as EnCellX is seeking to strengthen its balance sheet in the near term to fund continuing clinical development.\u201d<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>About Cellect Biotechnology Ltd.<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of cell-based therapies.<\/p>\n<p align=\"justify\">The Company\u2019s technology is expected to provide researchers, clinical community, and pharma companies with the tools to rapidly isolate specific cells in quantity and quality allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company\u2019s current clinical trial is aimed at bone marrow transplantations in cancer treatment.<br \/>\u00a0\u00a0<br \/><strong><em>Forward Looking Statements <\/em><\/strong><\/p>\n<p align=\"justify\">This press release contains forward-looking statements about the Company\u2019s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as \u201cbelieve\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cplan\u201d, \u201cmay\u201d, \u201cshould\u201d, \u201ccould\u201d, \u201cmight\u201d, \u201cseek\u201d, \u201ctarget\u201d, \u201cwill\u201d, \u201cproject\u201d, \u201cforecast\u201d, \u201ccontinue\u201d or \u201canticipate\u201d or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect\u2019s expectations regarding its U.S. clinical trial. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company\u2019s history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company\u2019s ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company\u2019s ability to obtain regulatory approvals; the Company\u2019s ability to obtain favorable pre-clinical and clinical trial results; the Company\u2019s technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company\u2019s clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company\u2019s ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company\u2019s industry; unforeseen scientific difficulties may develop with the Company\u2019s technology; the Company\u2019s ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company\u2019s ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading \u201cRisk Factors\u201d in Cellect Biotechnology Ltd.\u2019s Annual Report on Form 20-F for the fiscal year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC\u2019s website, www.sec.gov, and in the Company\u2019s periodic filings with the SEC.\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Contact<\/strong><br \/>\n        <br \/>Cellect Biotechnology Ltd.<br \/>Yaron Ben-Oz, Chief Financial Officer<br \/>www.cellect.co<br \/>+972-9-974-1444<\/p>\n<p>Or<\/p>\n<p align=\"justify\">EVC Group LLC<br \/>Michael Polyviou<br \/>(732) 933-2754<br \/>mpolyviou@evcgroup.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTdmODFjYWYtNjBlMy00YjMxLTlkN2QtNGY2YmY5ODk5NzBiLTUwMDA2NDI1OA==\/tiny\/Cellect-Biotechnology-Ltd-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX \ufeffTel Aviv, Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: \u201cAPOP\u201d), announced the first ApoGraftTM transplantation in a Leukemia patient in the Company\u2019s clinical trial at Washington University in the U.S. ApoGraftTM is a product based on the Company\u2019s cell selection technology designed to optimize immune therapy, in this application &#8211; prevent graft-versus-host disease (GVHD) following bone marrow transplantation. Following the closing of the previously announced strategic merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraftTM development will be pursued by EnCellX, the privately held U.S. based company that is acquiring Cellect\u2019s proprietary technology concurrently with such merger. The trial &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534150","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX \ufeffTel Aviv, Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: \u201cAPOP\u201d), announced the first ApoGraftTM transplantation in a Leukemia patient in the Company\u2019s clinical trial at Washington University in the U.S. ApoGraftTM is a product based on the Company\u2019s cell selection technology designed to optimize immune therapy, in this application &#8211; prevent graft-versus-host disease (GVHD) following bone marrow transplantation. Following the closing of the previously announced strategic merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraftTM development will be pursued by EnCellX, the privately held U.S. based company that is acquiring Cellect\u2019s proprietary technology concurrently with such merger. The trial &hellip; Continue reading &quot;Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T20:23:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S.\",\"datePublished\":\"2021-09-02T20:23:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/\"},\"wordCount\":897,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/\",\"name\":\"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA==\",\"datePublished\":\"2021-09-02T20:23:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/","og_locale":"en_US","og_type":"article","og_title":"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S. - Market Newsdesk","og_description":"Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX \ufeffTel Aviv, Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: \u201cAPOP\u201d), announced the first ApoGraftTM transplantation in a Leukemia patient in the Company\u2019s clinical trial at Washington University in the U.S. ApoGraftTM is a product based on the Company\u2019s cell selection technology designed to optimize immune therapy, in this application &#8211; prevent graft-versus-host disease (GVHD) following bone marrow transplantation. Following the closing of the previously announced strategic merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraftTM development will be pursued by EnCellX, the privately held U.S. based company that is acquiring Cellect\u2019s proprietary technology concurrently with such merger. The trial &hellip; Continue reading \"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T20:23:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S.","datePublished":"2021-09-02T20:23:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/"},"wordCount":897,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/","name":"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA==","datePublished":"2021-09-02T20:23:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc2MiM0Mzg3Nzk0IzUwMDA2NDI1OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellect-biotechnology-announces-the-apograft-bone-marrow-transplantation-of-first-patient-in-u-s\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cellect Biotechnology Announces the ApoGraft\u2122 Bone Marrow Transplantation of First Patient in U.S."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534150"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534150\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}